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regarding their use in cervical cancer. Here, we present a case of
multiple bone metastases arising after concurrent chemoradiation for
cervical cancer in a patient with long-term disease-free survival (DFS)
after concurrent chemotherapy with BPs.
Case report
A 66-year-old female patient ﬁrst presented to our hospital in
2005 with lower abdominal pain and macroscopic hematuria. The
patient was diagnosed with cervical cancer (FIGO stage IVa), andnode or distant metastases. Primary concurrent chemoradiotherapyIntroduction
Cervical cancer is a leading cause of cancer-related deathworldwide.
Themost common sites for the hematogenous spread of cervical cancer
are the lungs, liver, and bone (Hong et al., 2004; Hage et al., 2000).
Clinical incidence of bone metastases was reported in 3.8% of 1053
patients with cervical cancer by Nobunaga et al. (1988) and in 4.4% of
1252 patients with cervical cancer by Blythe et al. (1975). Symptomatic
bone metastases cause severe pain or pathological fractures, which
drastically decrease the patient's quality of life. In an autopsy study,
Abdul-Karim et al. (1990) and Disibio and French (2008) reported the
incidence of bone metastases from cervical cancer to be 6.3% and 8.6%,
respectively. Moriwaki noted bone metastases in 18.6% of 6109
cadavers with primary cervical cancer from a report of the Japanese
Society of Pathology (Moriwaki, 2007).
Early detection and proper palliative care, such as treatment
with bisphosphonates (BPs) or denosumab, could help avoid these
skeletal-related events. In cervical cancer, treatment of bonemetastases
is usually aimed at palliation and not prolongation of patient survival
(Thanapprapasr et al., 2010). Numerous clinical and preclinical studies
have examined the anti-cancer effect of BPs (Gnant and Clézardin,d Gynecology, Hyogo College of
, Japan. Fax: +81 798 46 4163.
).
Inc. Open access under CC BY license.histological analysis determined squamous cell carcinoma. Routine
computed tomography (CT) did not detect any apparent lymph
(CCRT) consisting of whole-pelvis and paraaortic external beam
radiotherapy of 50 and 45 Gy/25 fractions, respectively, was conducted
with high-dose-rate intracavitary brachytherapy consisting of 25 Gy/5
fractions. The chemotherapy protocol consisted of intrauterine arterial
administration of cisplatin (70 mg/m2) every 3 weeks but was only
conducted once due to the development of grade 4 neutropenia.
Weekly intravenous (IV) administration of cisplatin with radiotherapy
had been the standard mode of administration for several years,
because therewere no randomized trials that supported the superiority
of intra-arterial (IA) infusion of cisplatin with radiation. However, with
regard to the primary treatment of stage IVa cervical cancer, IA infusion
of cisplatin, followed by radical hysterectomy for local control, DFS,
and overall survival (OS), was superior to IV administration in the
neoadjuvant setting of our series of 3 phase II clinical trials. This infusion
technique was also examined at another institution during CCRT;
therefore, we adopted the IA infusion of cisplatin with radiotherapy in
this case after obtaining written informed consent. Four months after
completion of the primary treatment, the patient complained of slight
right inguinal pain. Skeletal scintigraphy revealed multiple pelvic
bone metastases (Fig. 1A) while magnetic resonance imaging (MRI)
revealed a tumor that was not observed at the time of completion of the
primary treatment (Fig. 2B). Laboratory tests showed elevated serum
alkaline phosphatase (ALP) levels of 357 mIU/ml and N-telopeptide
(NTx) levels of 26.7 nM BCE/L. As the pelvic metastatic lesions were
located in the previous radiation ﬁeld, concurrent chemotherapy with
BP was conducted. The chemotherapy regimen consisted of intravenous
nedaplatin, a cisplatin analogue, at a dose of 80 mg/m2 every month for
6 cycles. Because zoledronic acid (ZOL) was not available in Japan at the
time, weekly intravenous treatment with pamidronate (15 mg) was
administered for 12 months beginning on the ﬁrst day of nedaplatin
A B
Fig. 1. Technetium-99m skeletal scintigraphy of (A) multiple bone metastases 4 months after primary treatment and (B) 41 months after the last administration of pamidronate.
Arrows indicate the bone metastases.
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initiation of the treatment. Follow-up skeletal scintigraphy showed no
abnormal lesions, and the serum levels of ALP and NTx declined to the
normal range 41 months after the last administration of pamidronate
(Fig. 1B). The patient is currently alivewithout any recurrence 89 months
after the ﬁrst diagnosis of bone metastases.
Discussion
Weekly IV administration of cisplatin with radiotherapy has been
the standard mode of administration. However, in the SWOG 8797
trial (Peters et al., 2000), concurrent chemoradiotherapy consisting
of a bolus dose of cisplatin (70 mg/m2) and a 96-hour infusion
of ﬂuorouracil (1000 mg/(m2 · d)) every 3 weeks for 4 cycles im-
proved progression-free survival and OS in the adjuvant setting after
surgery. In the neoadjuvant chemotherapy setting of our series of 3
phase II clinical trials (Adachi et al., 2001; Tsubamoto et al., 2012,
2013), IA administration of cisplatin was superior to IV administration
for local control, DFS, and OS. Kawase et al. reported concurrent
chemoradiotherapy consisting of IA infusion of cisplatin (70 mg/m2)
and a 96-hour IV infusion of ﬂuorouracil (700 mg/(m2 · d)) every
3 weeks for 2 cycles (Kawase et al., 2006). Therefore, we adopted the
IA infusion of cisplatin concurrent with radiotherapy in this case after
obtaining written informed consent.A
Fig. 2. T1-weighted magnetic resonance imaging with contrast enhancement (A) at the tim
Arrows indicate 1 of the new lesions.The prognosis of patients with primary cervical cancer is poor
upon the diagnosis of bone metastases.Blythe et al. (1975) reported
that 96% of 55 cases had died within 18 months of diagnosis, while
Matsuyama et al. (1989) reported that 60% of 48 cases had died
within 6 months. Only 3 patients, who had received radiotherapy
followed by chemotherapy, survived over 2 years with the longest
survivor having lived for 3 years. Thanapprapasr et al. (2010)
reported that the median survival time for patients with cervical
cancer and bone metastases was 7 months, and among 51 patients,
only 1 patient with pelvic-only metastases lived for more than
5 years, having died 90 months after the diagnosis of bone
metastases, following an undescribed treatment schedule.
The aim of treatment for bone metastases is usually palliation.
The major clinical presentation is pain, and, to achieve pain
relief, radiation therapy or administration of BPs, denosumab, or
strontium-89 is usually conducted. More than half of the cervical
cancer cases show extraskeletal distant metastases (Thanapprapasr
et al., 2010), and systemic treatment of chemotherapy is also
conducted. Despite integrated treatment and care for bone metasta-
ses, patient survival is short and hospice enrollment is discussed.
In the present case, themetastatic lesionswere presentwithin a pre-
viously irradiated zone of primary external radiation, and additional ra-
diation therapy was not applicable. Early occurrence of the bone
metastases after CCRT was associated with a poor response to theB
e of completion of the primary treatment and (B) 4 months after primary treatment.
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Tanioka et al., 2011).
The anti-cancer activity of BPs in a randomized clinical trial (RCT)
was ﬁrst demonstrated by Diel et al. in 1998. The incidence of distant
bonemetastases following breast cancerwas reduced by a daily oral ad-
ministration of clodronate, a ﬁrst-generation BP, for 2 years. Since this
report, numerous RCTs have been conducted using BPs in cases of breast
cancer and other solid tumors (Gnant and Clézardin, 2012). In theMed-
ical Research Council PR05 and PR04 randomized controlled trials, use
of clodronate improved OS in metastatic prostate cancer patients
(Dearnaley et al., 2009). Recent reports of ABCSG-12, ZO-FAST, and
AZURE trials suggest synergic anti-cancer effects of ZOL and standard
treatments in postmenopausal women with breast cancer, although
the precise mechanisms behind this effect remains unknown (Gnant
et al., 2009; Coleman et al., 2011, 2013). The anti-cancer beneﬁts of
ZOL were also demonstrated in metastatic bladder and lung cancer
(Zaghloul et al., 2010; Zarogoulidis et al., 2009).
Preclinical studies have demonstrated the antitumor activity of BPs
in the bone marrow microenvironment. By inhibiting the activity of
farnesyl diphosphate synthase, a key enzyme in the mevalonate path-
way, tumor cells show reduced potential for migration, proliferation,
and angiogenesis and increased apoptosis. Decreased osteoclast forma-
tion and activity reduces the level of growth factors in the bonemarrow
microenvironment. As a result, apoptosis of cancer cells is expected
with synergic antitumor activity of the cytotoxic drugs. Recent clinical
studies showed that the circulating and disseminated tumor cells in
the blood and bonemarrow, respectively, which are relatively dormant
and escape cytotoxic drug activity, were reduced by the administration
of BPs (Gnant and Clézardin, 2012).
Recently, we surveyed metastatic lesions after serological or
radiological recurrence by routine use of 18F-ﬂuorodeoxyglucose
positron emission tomography–CT (PET/CT). Because PET is more
sensitive than CT and more speciﬁc than MRI, early detection of
bone metastases was increased at our institute.
Though irradiated bone-only metastases in primary cervical cancer
are extremely rare, the combination of chemotherapy with BP treat-
mentmight be useful for controlling bonemetastases in cervical cancer.
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